TY - JOUR T1 - First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients JF - Journal of Nuclear Medicine JO - J Nucl Med DO - 10.2967/jnumed.120.249029 SP - jnumed.120.249029 AU - Vikas Prasad AU - Friedemann Zengerling AU - Jochen P Steinacker AU - Christian Bolenz AU - Meinrad Beer AU - Thomas Wiegel AU - Matthias Eiber AU - Neil Fleshner AU - Ambros J Beer Y1 - 2020/11/01 UR - http://jnm.snmjournals.org/content/early/2020/11/27/jnumed.120.249029.abstract N2 - Synergistic effects of immunotherapy with pembrolizumab or drugs targeting DNA damage e.g. olaparib could be used to overcome the limitations of radioligand therapy (RLT) with Lu-177 prostate specific membrane antigen (PSMA) in metastasized castrate resistant prostate cancer (mCRPC) patients. Here, we present two patients receiving such combination / sequential therapies. Methods: RLT was performed at 6-8 week intervals after they either exhausted or were considered unfit for all approved conventional treatment. Patient 1 was on pembrolizumab for his squamous cell carcinoma of the skin whereas patient 2 received RLT sequentially 4 weeks after a 3 months monotherapy with olaparib. Results: Both patients tolerated RLT without any significant hematotoxicity. Patient 2 showed radiological and biochemical response whereas patient 1 achieved PSA stabilization after 3 therapy cycles. Conclusion: These cases indicate that RLT in combination with pembrolizumab or sequentially after olaparib might be well tolerated in single patients. ER -